While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...

National Geographic photographer Josh Cogan captures the quiet power of Hawaii’s ocean life, revealing how resilience shows ...

The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

The hybrid CME/CE event featured expert sessions on neurological disorders, emerging technologies, and evidence-based care, strengthening the knowledge and skills of clinicians across the neurology ...

Makueni’s leadership demonstrates how devolved governance can drive real impact by linking ecological farming, livelihoods, ...

Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive ...

HK Innoen is accelerating the expansion of its portfolio in geriatric and metabolic diseases by launching full-scale development of a treatment for ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

The previous quarter showed revenue of $396k and a loss of $36.77 million. This valuation on DNTH is abysmal. Price-to-Sales ...